Reports Q2 revenue $7.1B, consensus $6.96B. Biktarvy sales increased 9% y/y to $3.5B. “This was a very successful second quarter for Gilead (GILD), including the FDA approval for Yeztugo as the world’s first twice-yearly HIV prevention option,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the diversity of our portfolio. As we enter the third quarter, we are increasing revenue and earnings guidance for the year, and look forward to delivering continued innovation and growth across our core therapeutic areas.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Notable companies reporting after market close
- Gilead Sciences’ Promising Phase 2 Study on Ulcerative Colitis Treatment
- Options Volatility and Implied Earnings Moves Today, August 07, 2025
- Gilead Sciences’ Promising Phase 3 Study on Sacituzumab Govitecan for Lung Cancer
- Gilead Sciences Completes Insightful Study on Advanced Breast Cancer in Spain